2022年10月25日

Los Altos Alto神經科學,總部neuro-tech公司專門從事精密精神病學,提出了m係列B 35美元融資。圓是由Lightswitch資本和Alkeon首都Sobrato資本的參與,諾華製藥公司英勇Equity Partners, Korify資本,葡萄樹,Gaingels, Apeiron組,尼企業,溫德姆合資企業的合作夥伴。結合B係列融資,Lightswitch資本的首席執行官,克裏斯托弗·考克斯和Alkeon資本董事總經理Jeff Chen博士加入中音的董事會。此外,鮑勃Baloh,醫學博士,Ph.D., global head of neuroscience at the Novartis Institutes for BioMedical Research (NIBR), will join as a board observer. The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder in addition to continued development on other programs within its clinical-stage precision psychiatry pipeline. Proceeds from the financing will also be used to progress the company’s artificial intelligence-enabled brain biomarker platform and launch new clinical trials in areas of high unmet medical need. Alto will report Phase 2a data in early 2023 and further anticipates Phase 2b data readouts by early 2024. Led by Amit Etkin, M.D., Ph.D., founder and chief executive officer, Alto Neuroscience provides a precision psychiatry by developing targeted medicines to help patients get better. Differences in individuals’ biology impact how they respond to treatment. Its Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. FinSMEs 26/10/2022